Hematologic dysfunction and myeloid neoplasm risk in patients treated with lutetium-177 prostate specific antigen membrane therapyYael Kusne, Mrinal M. Patnaik, Miguel Muniz et al.|Haematologica|2025Cited by 3
LuRa: Efficacy and Safety of Radium-223 Following [177Lu]Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate CancerJabra Zarka, Daniel S. Childs, Ronit Juthani et al.|Clinical Genitourinary Cancer|2026Cited by 0